Complementary adenoviral vector systems and cell lines

Details Complementary adenoviral vector systems and cell lines Complementary adenoviral vector systems and cell lines

2007-03-27

2007-03-27

Priebe, Scott D. (Department: 1633)

Chemistry: molecular biology and microbiology

Micro-organism, tissue cell culture or enzyme using process...

Preparing compound containing saccharide radical

C435S320100, C435S325000, C435S366000, C435S456000, C424S093200

Reexamination Certificate

active

09964065

ABSTRACT:
The present invention provides multiply deficient adenoviral vectors and complementing cell lines. Also provided are recombinants of the multiply deficient adenoviral vectors and a therapeutic method, particularly relating to gene therapy, vaccination, and the like, involving the use of such recombinants.

REFERENCES:
patent: 4405712 (1983-09-01), Vande Woude
patent: 4497796 (1985-02-01), Salser et al.
patent: 4727028 (1988-02-01), Santerre et al.
patent: 4740463 (1988-04-01), Weinberg et al.
patent: 5190931 (1993-03-01), Inouye
patent: 5208149 (1993-05-01), Inouye
patent: 5518913 (1996-05-01), Massie et al.
patent: 5700470 (1997-12-01), Saito et al.
patent: 5851806 (1998-12-01), Kovesdi et al.
patent: 5994106 (1999-11-01), Kovesdi et al.
patent: 6040174 (2000-03-01), Imler et al.
patent: 6127175 (2000-10-01), Vigne et al.
patent: 6133028 (2000-10-01), Imler et al.
patent: 6482616 (2002-11-01), Kovesdi et al.
patent: 94/68503 (1994-12-01), None
patent: 94/72646 (1995-01-01), None
patent: 95/28533 (1996-03-01), None
patent: 2053187 (1993-04-01), None
patent: 2117668 (1995-09-01), None
patent: 2707664 (1995-01-01), None
patent: WO 94/08026 (1994-04-01), None
patent: WO 94/11506 (1994-05-01), None
patent: WO 94/12649 (1994-06-01), None
patent: WO 94/26914 (1994-11-01), None
patent: WO 94/28152 (1994-12-01), None
patent: WO 94/28938 (1994-12-01), None
patent: WO 95/00655 (1995-01-01), None
patent: WO 95/02697 (1995-01-01), None
patent: WO 95/16772 (1995-06-01), None
patent: WO 95/26411 (1995-10-01), None
patent: WO 95/27071 (1995-10-01), None
patent: WO 96/13596 (1996-05-01), None
patent: WO 96/14061 (1996-05-01), None
patent: WO 96/18418 (1996-06-01), None
patent: WO 96/22378 (1996-07-01), None
patent: WO 94/24297 (1999-10-01), None
Leza et.al; Independent Cyclic AMP and EIA Induction of Adenovirus Early Region 4 Expression 1989, Journal of Virology, vol. 63, No. 7: 30457-3064.
Wang et.al.; A packaging cell line for propagation of reombinant adenovirus vectors containing two lethal gene-region deletions, 1995, Gene Therapy 2: 775-783.
Klessig et.al.; Introduction, Stable Integration, and Controlled Expression of a Chimeric Adenovirus Gene Whose Product Is Toxic Recipient Human Cell, 1984, Molecular and Cellular Biology: 1354-1362.
Weinberg et.al.; A cell line that supports the growth of a defective early region 4 delection mutant of human adenovirus type 2, 1983, Proc. Natl. Acad.Sci., vol. 80: 5383-5386.
Imler et.al.; Novel complementation cell lines derived from human lung carcinoma A549 cells support growth of E1-deleted adenovirus vectors, 1996, Gene Therapy3:75-84.
Armentano et.al.; Characterization of an Adenovirus Gene Transfer Vector Containing an E4 Deletion, 1995, Human Gene Therapy 6: 1343-1353.
Grable et al. “Adenovirus type 5 packaging domain is composed of a repeated element that is functionally redundant,” J. Virol. 64 (5): 2047-2056, May 1990.
Barr et al.,Gene Ther., 1, 51-58 (1994).
Berkner et al.,Nucl. Acids Res., 11 (17), 6003-6020 (Sep. 1983).
Berkner,BioTechniques, 6(7), 616-629 (Jul./Aug. 1988).
Boucher et al.,Hum. Gene Ther., 5, 615-639 (1994).
Brough et al.,Virology, 190 (2), 624-634 (Oct. 1992).
Brough et al.,Virology, 196 (1), 269-281 (1993).
Crystal et al.,Nature Med., 1 (1), 15-17 (1995).
Davidson et al.,J. Virol., 61 (4), 1226-1239 (Apr. 1987).
DeMatteo et al.,Transplantation 63(2), 315-319 (1997).
Engelhardt et al.,PNAS USA, 91 (13), 6196-6200 (Jun. 1994).
Englehardt et al.,Hum. Gene Ther., 4 (6), 759-769 (Dec. 1993).
Fallaux et al.,Hum. Gene Ther., 7, 215-222 (Jan. 20, 1996).
Friedmann et al.,Scientific American, 96-101 (Jun. 1997).
Gilardi et al.,FEBS Lett., 267 (1), 60-62 (Jul. 1990).
Graham et al.,J. Gen. Virol., 36 (1), 59-74 (Jul. 1977).
Kreeger, “Hot Papers: Gene Therapy,”The Scientist, 10 (4) (Feb. 19, 1996).
Krougliak et al.,Hum. Gene Ther., 6, 1575-1586 (Dec. 1995).
Lemarchand et al.,PNAS USA, 89 (14), 6482-6486 (Jul. 15, 1992).
Mastrangeli et al.,J. Clin. Invest., 91 (1), 225-234 (Jan. 1993).
Mittereder et al.,Hum. Gene Ther., 5 (6), 771-729 (Jun. 1994).
Morin et al.,Mol. Cell Biol., 9 (10), 4372-4380 (Oct. 1989).
Orkin et al.,Report and Recommendations to the Panel to Assess NIH Investment in Research on Gene Ther. (1995).
Rosenfeld et al.,Cell, 68 (1), 143-158 (Jan. 10, 1992).
Schaack et al.,J. Virol., 69, 4079-4085 (Jul. 1995).
Schulick et al.,J. Clin. Invest., 99 (2), 209-219 (1997).
Simon et al.,Hum. Gene Ther., 4 (6), 771-780 (Dec. 1993).
Trapnell et al.,Curr. Opin. Biotechnol., 5, 617-625 (1994).
Verma et al.,Nature, 389, 239-242 (1997).
Vos et al.,Virology, 172 (2), 634-642 (Oct. 1989).
Yang et al.,PNAS USA, 91 (10), 4407-4411 (May 1994).
Yeh et al.,J. Virol., 70 (1), 559-565 (Jan. 1996).
Brough et al., “A gene transfer vector-cell line system for complete functional complementation of adenovirus early regions E1 and E4, ”J. Virol., 70(9),6497-6501 (1996).
Brunet et al., “Concentration dependence of transcriptional transactivation in inducible E1A-containing human cells, ”Mol. Cell. Biol., 8(11), 4799-4807 (Nov. 1988).
Byrd et al., “Malignant transformation of human embryo retinoblasts by cloned adenovirus 12 DNA,”Nature, 298(5869), 69-71 (Jul. 1, 1982).
Crystal et al., “Administration of an adenovirus containing the human CFTR cDNA to the respiratory track of individuals with cystic fibrosis,”Nature Genet.,8, 42-51 (1994).
Gallimore et al., “Properties of rat cells transformed by DNA plasmids containing adenovirus type 12 E1 DNA or specific fragments of the E1 region: comparison of transforming frequencies,”Cancer Res., 45(6), 2670-2680 (Jun. 1985).
Grodzicker et al., “Expression of unselected adenovirus genes in human-cells co-transformed with the HSV-1-TK gene and adenovirus 2 DNA,”Cell,21(2), 453-463 (Sep. 1980).
Ketner et al., “Complementation of adenovirus E4 mutants by transient expression of E4 cDNA and deletion plasmids,”Nucl. Acids Res., 17(8), 3037-3048 (Apr. 25, 1989).
Klinman, “Introduction to the issues: Viral vectors and potential problems in their use,”Developments in the Biological Standardization, 76,299-300 (S.Karger AG, Basel, Switzerland, 1992).
Lewis et al., “Viral messenger RNA in six lines of adenovirus-transformed cells,”Virology, 115(2), 345-360 (Dec. 1981).
Roberts et al., “Individual adenovirus type 5 early region 1A gene products elicit distinct alterations of cellular morphology and gene expression,”J. Virol., 56(2), 404-413 (Nov. 1985).
Wang et al., “Second-generation adenovirus vectors,”Nature Med., 2(6), 714-716 (1996).
Yang et al., “Inactivation ofE2ain recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis,”Nature Gen., 7,362-369 (1994).
Zhou et al., “Progress towards development of an adenoviral vector with deletions of E1 and E2a,”J. Cell. Biochem., Supp. 21A,434 (1995).

Affiliated with

Also associated with

Rating

Complementary adenoviral vector systems and cell lines does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Complementary adenoviral vector systems and cell lines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Complementary adenoviral vector systems and cell lines will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3756491